Screener
Mirum Pharmaceuticals, Inc. MIRM Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $176.24M+37.9% | $159.88M+43.3% | $148.93M+49.8% | $133.01M+47.2% | $127.79M+64.1% | ||
| $90.53M+96.5% | $97.91M+139% | $51.11M+16.1% | $42.96M+35.5% | $46.07M+41.0% | ||
| $81.47M+28.7% | $96.33M+66.9% | $74.13M+30.4% | $61.91M+22.5% | $63.29M+28.6% | ||
| $218.78M+64.8% | $949.35M+649% | $153.5M+24.2% | $130.41M+26.5% | $132.77M+30.0% | ||
| -$42.54M-753% | -$789.47M-5,100% | -$4.57M+81.1% | $2.6M+121% | -$4.99M+79.4% | ||
| -24.1%-20.2pp | -493.8%-480pp | -3.1%+21.3pp | 2%+16.0pp | -3.9%+27.2pp | ||
| $2.62M-27.1% | $3.62M+0.6% | $3.6M+0.5% | $3.61M+0.6% | $3.59M+0.6% | ||
| -$24.23M-28,279% | $0-100% | $0-100% | $395K+136% | $86K-72.4% | ||
| -$65.54M-1,101% | -$789.68M-5,686% | -$4.96M+79.6% | $2.64M+119% | -$5.46M+77.3% | ||
| $1.69M+320% | $475K-53.8% | $767K— | -$262K-176% | $402K-36.7% | ||
| -$67.23M-1,047% | -$790.16M-5,284% | -$5.73M+75.9% | $2.91M+120% | -$5.86M+76.2% | ||
| -38.1%-33.6pp | -494.2%-481pp | -3.8%+20.1pp | 2.2%+17.9pp | -4.6%+27.1pp | ||
| -$1.06-783% | -$13.43-4,377% | -$0.12+75.5% | $0.05+117% | -$0.12+76.9% | ||
| -$35.6M-3,437% | -$782.59M-8,471% | $1.51M+108% | $8.67M+231% | $1.07M+106% | ||
| -20.2%-21.0pp | -489.5%-481pp | 1%+19.3pp | 6.5%+13.8pp | 0.8%+24.4pp | ||
| -$42.54M-753% | -$789.47M-5,100% | -$4.57M+81.1% | $2.6M+121% | -$4.99M+79.4% |
FAQ
- What is Mirum Pharmaceuticals, Inc.'s revenue?
- Mirum Pharmaceuticals, Inc. (MIRM) generated $618.1M in revenue over the trailing twelve months, up 44.0% year over year.
- Is Mirum Pharmaceuticals, Inc. profitable?
- Mirum Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $860.2M over the trailing twelve months, a -139.2% net margin.
- What is Mirum Pharmaceuticals, Inc.'s earnings per share?
- Mirum Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-14.56.
- Where does Mirum Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
